|

Fianlimab Clinical Trials

11 actively recruiting trials across 11 locations

Also known as: Anti-LAG-3 MoAb, Anti-LAG-3 MoAb REGN3767, REGN 3767, REGN3767, WHO 11182

Pipeline

Phase 1: 1Phase 2: 8Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Regeneron Pharmaceuticals3
  • University of Wisconsin, Madison1
  • Thomas Jefferson University1
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
  • Nitin Ohri1

Indications

  • Cancer11
  • Lung Cancer2
  • Advanced Renal Cell Carcinoma (aRCC)1
  • Locally Advanced Basal Cell Carcinoma1
  • Clear Cell Renal Cell Carcinoma (ccRCC)1

Birmingham, Alabama1 trial

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The University of Alabama at Birmingham

Phase 2

Chandler, Arizona1 trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Ironwood Cancer & Research Centers

Phase 3

La Jolla, California1 trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Miami, Florida1 trial

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

University of Miami Health System

Phase 2

Baltimore, Maryland1 trial

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Johns Hopkins SKCCC

Phase 2

Rochester, Minnesota1 trial

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

Mayo Clinic in Rochester

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites)

Phase 2

New York, New York1 trial

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Columbia University Irving Medical Center/ New York Presbyterian Hospital

Phase 2

The Bronx, New York1 trial

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Montefiore Einstein Comprehensive Cancer Center (MECCC)

Phase 2

Nashville, Tennessee1 trial

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Vanderbilt-Ingram Cancer Center

Phase 2

Madison, Wisconsin1 trial

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

University of Wisconsin Carbone Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.